Document is current
Any future updates will be listed below
-
Authors
Ntanasis-Stathopoulos, Ioannis https://orcid.org/0000-0002-6328-9783
Filippatos, Charalampos
Malandrakis, Panagiotis
Koutoulidis, Vassilis
Trapali, Maria
Kastritis, Efstathios https://orcid.org/0000-0001-8191-5832
Terpos, Evangelos https://orcid.org/0000-0001-5133-1422
Dimopoulos, Meletios-Athanasios https://orcid.org/0000-0001-8990-3254
Gavriatopoulou, Maria https://orcid.org/0000-0002-6244-1229
- License Information
-
More Information
Article History
Received: 12 January 2025
Revised: 28 May 2025
Accepted: 23 June 2025
First Online: 2 July 2025
Competing interests
: INS declares honoraria from Janssen. PM declares honoraria from Janssen. EK declares honoraria from Amgen, Janssen, GSK, and Pfizer. MAD declares honoraria from Abbvie, Amgen, Bristol Myers Squibb, GSK, Janssen, Karyopharm, Pharmacyclics Inc, Pfizer, Sanofi, and Takeda. ET declares honoraria from Amgen, Astra/Zeneca, Bristol Myers Squibb, Eusa Pharma, GSK, Integris Pharma, Janssen, Pfizer, Sanofi, and Takeda. MG declares honoraria from GSK, Janssen, Sanofi, Abbvie, Amgen, and Takeda. The other authors declare no conflict of interest.
: This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. As this study is based solely on previously published peer-reviewed data and does not involve human participants, interventions, or identifiable personal data, it did not require approval by an ethics committee or informed consent.
